Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, posted on X:
“BRAFV600E is present in about 10% of patients with Colorectal Cancer.
Important to recognize since treatment and strategies might differ. Two trials have shown the addition of immunotherapy to the targeted therapies as promising.”
